Clinical Trials Browser

Interventional × dostarlimab × Dermatologic × Clear all

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

463 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Phase 2 Active not recruiting

48 enrolled

Dermatologic

Melanoma

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT05060432 2024-06-21

TIG-006

Phase 1/2 Active not recruiting

153 enrolled

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

Clinical Trials

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

TIG-006